A growing number of patients require oral anticoagulant (OAC) after undergoing percutaneous coronary intervention (PCI) with stent implantation due to the development of atrial fibrillation, but the optimal antithrombotic regimen remains controversial in these patients.Methods:
We systematically searched PUBMED, EMBASE, and CENTRAL from inception until September 2016 for randomized controlled trials or cohort studies that evaluated the comparative effects of TT versus DT. Relative risks (RRs) with 95% confidence intervals (95% CIs) were pooled by a random-effects model or a fixed-effects model.Results:
Twelve studies with a total of 30,823 patients were included in this analysis, including 6134 in the TT group and 24,689 in the DT group. No significant differences were found between the TT group and the DT group regarding major adverse cardiovascular events (MACE) (RR = 0.82, 95% CI: 0.58–1.17; I2 = 87.3%), stroke (RR = 1.08, 95% CI: 0.56–2.07; I2 = 65.5%), all-cause mortality (RR = 0.90, 95% CI: 0.54–1.51; I2 = 79.1%), or stent thrombosis (RR = 0.71, 95% CI: 0.41–1.24; I2 = 12.7%), and lower rates were observed for myocardial infarction (RR = 0.59, 95% CI: 0.50–0.70; I2 = 31.1%) and major bleeding with TT (RR = 0.86, 95% CI: 0.74–0.99; I2 = 24.3%). Meanwhile, we also found that compared with TT, OAC with clopidogrel treatment shows equal efficacy and safety outcomes.Conclusion:
In patients on OAC undergoing PCI with stent implantation, compared with DT, TT shows equal effectiveness in terms of MACE, stroke, all-cause mortality, and stent thrombosis and lower risks of myocardial infarction and major bleeding. However, similar efficacy and safety outcomes were observed between the TT group and the OAC along with clopidogrel group.